238 related articles for article (PubMed ID: 19793723)
1. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches.
Kumakura Y; Cumming P
Neuroscientist; 2009 Dec; 15(6):635-50. PubMed ID: 19793723
[TBL] [Abstract][Full Text] [Related]
2. PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent decline of [18F]fluorodopamine storage capacity.
Kumakura Y; Vernaleken I; Gründer G; Bartenstein P; Gjedde A; Cumming P
J Cereb Blood Flow Metab; 2005 Jul; 25(7):807-19. PubMed ID: 15729292
[TBL] [Abstract][Full Text] [Related]
3. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent decline of steady state dopamine storage capacity of human brain: an FDOPA PET study.
Kumakura Y; Vernaleken I; Buchholz HG; Borghammer P; Danielsen E; Gründer G; Heinz A; Bartenstein P; Cumming P
Neurobiol Aging; 2010 Mar; 31(3):447-63. PubMed ID: 18541344
[TBL] [Abstract][Full Text] [Related]
5. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
[TBL] [Abstract][Full Text] [Related]
6. Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease.
Kumakura Y; Danielsen EH; Gjedde A; Vernaleken I; Buchholz HG; Heinz A; Gründer G; Bartenstein P; Cumming P
Neuroimage; 2010 Feb; 49(4):2933-9. PubMed ID: 19941962
[TBL] [Abstract][Full Text] [Related]
7. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for [¹⁸F]FDOPA PET by a model with detailed dopamine pathway.
Matsubara K; Watabe H; Kumakura Y; Hayashi T; Endres CJ; Minato K; Iida H
Synapse; 2011 Aug; 65(8):751-62. PubMed ID: 21190220
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
11. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
12. Loss of metabolites from monkey striatum during PET with FDOPA.
Cumming P; Munk OL; Doudet D
Synapse; 2001 Sep; 41(3):212-8. PubMed ID: 11391782
[TBL] [Abstract][Full Text] [Related]
13. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
15. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
Nagasawa H; Tanji H; Itoh M; Itoyama Y
Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
[TBL] [Abstract][Full Text] [Related]
16. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
[TBL] [Abstract][Full Text] [Related]
17. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
[TBL] [Abstract][Full Text] [Related]
18. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDOPA kinetics in brain tumors.
Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
[TBL] [Abstract][Full Text] [Related]
20. [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease.
Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ
Neuroimage; 2012 Jan; 59(2):1080-4. PubMed ID: 21963917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
